AbbVie Analyst Price Targets - Benzinga

AbbVie Inc

ABBVNYSE

Trade with Public

Trade with Public

$260.15

0.160.06%

Ult. Agg.: Sep 2, 1:56 PM

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Dividendi Confronta Opzioni Rapporto azionario

AbbVie Analyst Price Targets

Wall Street analyst price targets and consensus rating for AbbVie (ABBV).

Price Target Range — 8 Quarters

Analyst Consensus — 25 Analysts

21Buy

4Hold

Consensus RatingBuy# Analysts25Avg. Consensus PT$263Upside to Avg. PT+1.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 20, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$298→$303
Aug 17, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$295→$300
Aug 13, 2026	Wolfe Research	Alexandria Hammond	Upgrade	Peer Perform→Outperform	$300
Aug 11, 2026	BNP Paribas	Navann Ty	PT Raise	Neutral	$218→$247
Aug 10, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Raise	Outperform	$246→$260
Aug 6, 2026	Berenberg	Luisa Hector	Maintained	Buy	$275
Aug 5, 2026	Erste Group	Hans Engel	Upgrade	Hold→Buy	—
Aug 4, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$261→$288
Aug 3, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$278→$296
Aug 3, 2026	Canaccord Genuity	Gary Nachman	PT Raise	Buy	$282→$290
Aug 3, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$265→$285
Jul 31, 2026	TD Cowen	Steve Scala	Maintained	Buy	$280
Jul 31, 2026	William Blair	Matt Phipps	Maintained	Buy	—
Jul 29, 2026	Barclays	Emily Field	PT Raise	Overweight	$275→$300
Jul 22, 2026	Canaccord Genuity	Gary Nachman	PT Raise	Buy	$273→$282
Jul 15, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$230→$260
Jul 13, 2026	UBS	Michael Yee	PT Raise	Neutral	$230→$260
Jul 13, 2026	BMO Capital	Evan David Seigerman	PT Raise	Outperform	$258→$300
Jul 10, 2026	B of A Securities	Geoff Meacham	PT Raise	Buy	$234→$276
Jul 10, 2026	RBC Capital	Trung Huynh	PT Raise	Outperform	$260→$280

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $303

Piper Sandler analyst David Amsellem maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $298 to $303.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $300

Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $295 to $300.

Benzinga Newsdesk

PRO
Wolfe Research Upgrades AbbVie to Outperform, Announces $300 Price Target

Wolfe Research analyst Alexandria Hammond upgrades AbbVie (NYSE:ABBV) from Peer Perform to Outperform and announces $300 price target.

Benzinga Newsdesk

PRO
BNP Paribas Maintains Neutral on AbbVie, Raises Price Target to $247

BNP Paribas analyst Navann Ty maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $218 to $247.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on AbbVie, Raises Price Target to $260

Evercore ISI Group analyst Gavin Clark-Gartner maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $246 to $260.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on AbbVie, Raises Price Target to $288

Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $261 to $288.

Benzinga Newsdesk